<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655692</url>
  </required_header>
  <id_info>
    <org_study_id>SPLE-003-14W</org_study_id>
    <nct_id>NCT02655692</nct_id>
  </id_info>
  <brief_title>CAP-Ketamine for Antidepressant Resistant PTSD</brief_title>
  <official_title>CAP-Ketamine for Antidepressant Resistant PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brooke Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minneapolis Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as
      compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an
      active duty military and Veteran population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this 2-site clinical trial, intended to evaluate the safety and efficacy of repeated doses
      of ketamine for treatment resistant PTSD, Veterans and active duty military personnel who
      meet criteria for PTSD and the additional inclusion and exclusion criteria will be randomized
      to one of three treatment arms (placebo, low dose ketamine, high dose ketamine). Participants
      receive the study drug via intravenous infusion twice per week for 4-weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2016</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PTSD Checklist to measure change in PTSD symptoms from baseline to post-treatment (4 weeks)</measure>
    <time_frame>24-hours post-infusions; weekly for 4 weeks following last infusion</time_frame>
    <description>The PTSD Checklist (PCL) is a brief measure of the symptoms of Posttraumatic Stress Disorder. Item and total scores will be recorded and aggregated from all study participants.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>PTSD</condition>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose Ketamine (.20 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose Ketamine (.50 mg/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>FDA approved anesthetic medication with rapid acting antidepressant effects.</description>
    <arm_group_label>High Dose Ketamine</arm_group_label>
    <arm_group_label>Low Dose Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This is a saline placebo/non-active solution.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female Veterans or active duty military personnel between the ages of 18 and
             70 years

          -  diagnosis of PTSD

          -  history of trialing one or more antidepressant medications with little to no PTSD
             symptom improvement

          -  ability to provide written informed consent

        Exclusion Criteria:

          -  females who are currently pregnant or breastfeeding

          -  current high risk for suicide

          -  history of severe head injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John H. Krystal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Health Care System, Minneapolis, MN</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 7, 2016</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Veteran</keyword>
  <keyword>Military</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

